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NO mediates antifibrotic actions of L-arginine supplementation
following induction of anti-thy1 glomerulonephritis.
Background. l-Arginine plays a complex role in renal matrix
expansion, involving endogenous metabolism into nitric oxide
(NO), polyamines, L-proline and agmatine. Supplementing di-
etary l-arginine intake has been shown to limit transforming
growth factor (TGF)-1 overproduction and matrix accumula-
tion in rats with induced anti-thy1 glomerulonephritis (GN). The
present study tests the hypothesis that this beneficial effect on
in vivo TGF- overexpression is mediated via the generation
of NO.
Methods. One day after induction of anti-thy1 GN, male Wis-
tar rats fed a normal protein diet were assigned to the following
groups: (1) normal controls; (2) GN; (3) GN-Arg (plus 500 mg
l-arginine/day); (4) GN-Arg-NAME [plus 500 mg l-arginine/
day and 75 mg/L of the NO synthase inhibitor nitro-l-arginine-
methyl ester (L-NAME) in the drinking water]; and (5) GN-
Molsi (10 mg/day of the NO donor molsidomine). In protocol
1, treatment lasted until day 7, and in protocol 2, until day 12
after disease induction, respectively. Analysis included systolic
blood pressure, a glomerular histologic matrix score, and the
glomerular mRNA and protein expression of the key fibrogen
TGF-1, the matrix protein fibronectin, and the protease inhib-
itor plasminogen activator inhibitor type 1 (PAI-1).
Results. Blood pressure was normal in untreated anti-thy1
animals and not significantly affected by any of the treatments.
Compared to untreated nephritic rats, administration of both
l-arginine and molsidomine reduced glomerular TGF-1 over-
expression significantly and to a similar degree in both proto-
cols, while the beneficial effect of l-arginine was abolished
by concomitant NO synthesis inhibition. Glomerular matrix
accumulation, fibronectin and PAI-1 mRNA and protein ex-
pression closely followed the expression of TGF-1.
Conclusion. The present study shows that l-arginine’s anti-
fibrotic action in normotensive anti-thy1 GN is mainly medi-
ated by endogenous production of NO. The data suggest that
NO limits in vivo TGF- overexpression in a pressure-indepen-
dent manner and that NO donors may be of benefit in the
treatment of human fibrotic renal disease.
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Accumulation of extracellular matrix is a hallmark of
both acute and chronic renal disease [1]. Extracellular
matrix expansion is a uniform response to various injuri-
ous stimuli deriving from hypertension, inflammation,
hypoxia, or diabetes. At the molecular level, matrix expan-
sion results from increased synthesis of matrix proteins,
decreased degradation of matrix proteins, increased ex-
pression of cell-matrix receptors, and an orchestration of
these events by overproduction of the profibrotic cytokine
transforming growth factor (TGF)- [1]. The key role of
TGF- in fibrosis has been highlighted by experimental
studies demonstrating that specific antagonism of TGF-
markedly limits matrix expansion in both acute and chronic
renal disease [2, 3].
Endogenous l-arginine metabolism is involved in re-
nal matrix production and accumulation in a complex
manner [4–7]. Via three nitric oxide synthases (NOS),
l-arginine is involved in the regulation of renal vascular
pressure (endothelial NOS, eNOS), immune-mediated
kidney disease (inducible NOS, NOS II), and neuronal
control of the tubular-glomerular feedback (neuronal
NOS, NOS I). In addition, l-arginine is a precursor for the
generation of polyamines, L-proline and agmatine [4–9].
Polyamines are essential for cell proliferation; L-proline
is a key collagen constituent, and agmatine is a recently
discovered novel regulator of renal hemodynamics and
an endogenous inhibitor of other l-arginine–metaboliz-
ing pathways such as polyamine and inducible NO pro-
duction [8, 9].
Supplementing dietary l-arginine intake has been shown
to improve renal hemodynamics and to reduce matrix
expansion in many hypertensive models of kidney dis-
ease [4–7]. Since these effects were associated with signs
of increased endogenous NO production (plasma or uri-
nary nitrite/nitrate levels, NOx), it has been descriptively
assumed that enhanced vasodilatory endothelial NO pro-
duction is involved. However, more conclusive evidence
based on both a positive and negative intervention (con-
comitant inhibition of NO synthesis and use of an exclu-
sive NO donor, respectively), for instance, is missing.
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In addition to hypertensive kidney disease, l-arginine
supplementation has been found to limit TGF- over-
expression and matrix expansion in the model of acute
anti-thy1 glomerulonephritis (GN) in a pressure-inde-
pendent manner [10]. Since indices of endogenous NO
production were unaffected by l-arginine administration
in this study, it remained unclear which metabolite or
pathway mediates this effect, although a direct effect of
NO on TGF- expression appears to be a prime candidate.
The present study tests the hypothesis that the benefi-
cial action of l-arginine on TGF- overexpression in anti-
thy1 GN is mediated by the endogenous generation of
NO. Therefore, nephritic rats were treated with supple-
mental l-arginine, supplemental l-arginine and a low dose
of the NO synthase inhibitor L-NAME, or the NO donor
molsidomine. Treatment was begun one day after injec-
tion of anti-thy1 antibody. Seven days (protocol 1) or
12 days (protocol 2) after disease induction, actions on
blood pressure, plasma and urinary NOx levels, protein-
uria, glomerular matrix accumulation, and TGF-1, fi-
bronectin, and plasminogen activator inhibitor type 1
(PAI-1) expression were analyzed.
METHODS
Materials
Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma Chemical-
Aldrich Co. (Taufkirchen, Germany).
Animals
Male Wistar rats (200 to 270 g) were obtained from
Charles River (Sulzfeld, Germany). Animals were fed a
normal protein diet (22.5% protein, Altromin No. 1311,
Altromin, Lage, Germany) for at least three days before
the start of the experiment to allow equilibration. Animal
care and treatment were conducted in conformity with
the guidelines of the American Physiological Society and
were approved by local authorities. Animals were housed
in a constant temperature room with a 12-hour dark/12-
hour light cycle.
Induction of anti-thy1 glomerulonephritis
Glomerulonephritis was induced by tail vein injection
of the monoclonal anti-thy1 antibody OX-7 (1 mg/kg)
under light ether anesthesia. In the kidney, the mono-
clonal antibody binds to a thy1–like epitope on the sur-
face of mesangial cells and causes complement-depen-
dent cell lysis [11]. OX-7 was produced as previously
described [11]. Control animals were injected with equal
volumes of phosphate-buffered saline (PBS).
Treatments
All animals were fed a normal protein diet with 22.5%
casein and an l-arginine content of 0.87% (Altromin
No. 1311). Supplementation of dietary l-arginine intake
was carried out by adding 500 mg l-arginine to 25 g of
food. This leads to a comparable amount, as it is achieved
by adding 1% l-arginine to the drinking water, which has
been the most frequently used mode of l-arginine supple-
mentation in previous studies [4–7]. The food route was
chosen because it has been our experience that food intake
is more constant between animals and over time than
drinking volume. The NO synthase inhibitor L-NAME
is chemically unstable and was therefore given daily in
freshly prepared drinking water at a dose of 75 mg/mL.
L-NAME inhibits NO synthesis by all three NOS iso-
enzmyes [12]. The NO donor molsidomine was given with
the food at a dose of 10 mg per 25 g of food. The doses
were chosen on the basis of previous experiments in rat
models of renal disease [13–15]. Molsidomine is an inac-
tive prodrug. In the liver, molsidomine is enzymatically
converted to yield the active metabolite 3-morpholino-
sydnonimine-hydrochloride (SIN-1, linsidomine) [16]. One
molecule of SIN-1 spontaneously releases one molecule
of NO.
Experimental design
Two separate protocols were performed. In protocol 1,
the animals were sacrificed seven days after disease in-
duction, and in protocol 2, 12 days after disease induc-
tion, respectively. In both, treatment was started 24 hours
after anti-thy1 antibody injection, when mesangial cell
lysis is complete and the fibrotic response begins [11].
In both experimental protocols, rats were assigned to
the following groups: (1) normal controls (control, in-
jected with PBS, N 4); (2) anti-thy1 glomerulonephritis
without treatment (GN, N  12); (3) GN plus 500 mg
l-arginine per day (GN-Arg, N  12); (4) GN plus 500
mg l-arginine per day and 75 mg/L of the NOS inhibitor
L-NAME in the drinking water (GN-Arg-NAME, N 
12); and (5) GN plus 10 mg of NO donor molsidomine
per day (GN-Molsi, N  12).
Our main focus was on the interaction of NO with in
vivo expression of the key fibrosis mediator TGF-1. A
histologic matrix score was used to prove that the changes
in TGF- expression reflect the actual renal matrix accu-
mulation and indicate the in vivo activity of TGF-. Ex-
pression of the matrix component fibronectin was mea-
sured as an indicator for matrix production. The protease
inhibitor PAI-1 was used as marker of the matrix degrad-
ing system. Both fibronectin and PAI-1 are very sensitive
to the action of TGF- and therefore served as indicators
of the actual activity of TGF- in vivo. To characterize
endogenous NO generation, blood and urinary nitrite/
nitrate levels were also determined.
Body weight was determined at the beginning and end
of each experiment. Food and water intake was monitored
daily. Renal tissues were harvested at the end of each
experiment.
Peters et al: NO in acute renal matrix expansion 511
Measurement of systolic blood pressure and proteinuria
One day before the end of the experiment, systolic blood
pressure was measured in conscious animals by tail cuff
method as previously described [11]. During the following
24 hours, the rats were individually housed in metabolic
cages for urine collection. Urinary protein was measured
by a pyrogallol red method using a microplate technique
[17]. Proteinuria is expressed as mg protein/24 hours.
Sacrifice
At the end of each experiment, animals were anesthe-
tized with ether. Following a midline abdominal incision,
5 to 10 mL of blood were drawn from the abdominal
aorta and the kidneys were subsequently perfused with
30 mL ice-cold PBS. For histologic examination, cortical
tissue was fixed in 10% neutral buffered formalin. Glo-
meruli from individual rats were isolated by a graded
sieving technique (150, 125, 91, and 75 m mesh metal
sieves) as described previously [11].
Light and immunohistochemic microscopy
All microscopic examinations were performed in a
blinded fashion. Three m sections of paraffin-embed-
ded tissue were stained with periodic-acid Schiff (PAS).
Glomerular matrix expansion was evaluated as previ-
ously described [11]. Briefly, in 25 glomeruli of each rat,
the percentage of matrix-occupying area was rated from
0% to 100% and the mean was calculated. In protocol 1,
TGF-1 staining on renal tissues was performed using
a primary rabbit-anti-TGF- antibody (Santa Cruz Bio-
technology, Inc., Heidelberg, Germany) and a secondary
mouse anti-rabbit antibody coupled with the Envision
staining system (Dako Cytomation, Hamburg, Germany).
Glomerular TGF-1, fibronectin, and
PAI-1 protein expression
Glomeruli from individual rats were resuspended in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 0.1 U/mL insulin, 100 U/mL penicillin, 100
g/mL streptomycin, and 25 mmol N-2-hydroxyethyl-
piperazine-N-2-ethanesulfonic acid (HEPES) buffer.
After 48 hours incubation at 37C/5% CO2, supernatants
were harvested and stored at 20C until analysis of
glomerular TGF-1, fibronectin, and PAI-1 production.
TGF-1 production of cultured glomeruli was measured
after acid-activation using a commercially available en-
zyme-linked immunosorbent assay (ELISA) kit (TGF-
1; Duoset, R&D Systems, Wiesbaden, Germany) ac-
cording to the manufacturer’s instructions. Fibronectin
and PAI-1 synthesis were measured with modified inhibi-
tory ELISA according to published methods [18]. Three
samples from each rat were analyzed.
Glomerular TGF-1, fibronectin, and
PAI-1 mRNA expression
In protocol 1, glomerular total RNA was extracted
by a guanidinium isothiocyanate method using TrizolTM
reagent (Gibco BRL, Berlin, Germany) according to the
manufacturer’s instructions. The mRNA expression of
TGF-1, fibronectin, and PAI-1 were determined by a
standard relative reverse transcription (RT)-polymerase
chain reaction (PCR) method as previously described
[19]. The following primer pairs were used: GAPDH:
sense CCATCTTCCAGGAGCGAGAT, antisense GAT
GACCTTGCCCACAGCCT (24 cycles, 59C); TGF-1:
sense GGTGGCAGGCGAGAGCGCTGA, antisense
GGCATGGTAGCCCTTGGGCT (27 cycles, 64C); fi-
bronectin: sense GGTCCAAATCGGTCATGTTCCCA;
antisense GCCCCAGGTCTGCGGCAGTTGT (27 cy-
cles, 64C); PAI-1: sense CAGCATGTGGTCCAGGC
CTCCAAA, antisense TGTGCCGCTCTCGTTCACC
TCGATCT (27 cycles, 64C). PCR products were sepa-
rated on a 2% agarose gel and analyzed by an imaging
densitometer (Thyphoon 8600, Amersham Biosciences
Europe GmbH, Freiburg, Germany). The density of the
bands for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA was used as housekeeping gene. For
quantitation purposes, values of TGF-1, fibronectin,
and PAI-1 bands were divided by the band density for
GAPDH of the same sample.
NOx measurements
Nitrite and nitrate are stable oxidation end products
of NO and served as indicators of endogenous NO syn-
thesis [5]. Plasma and urinary NOx levels were measured
by the Griess reaction after nitrate reductase treatment
[20]. Briefly, blood plasma and urine samples were di-
luted in PBS and incubated at room temperature in the
presence of 0.05 mmol/L nicotinamide adenine dinucleo-
tide phosphate (NADPH) and 0.05 U of nitrate reduc-
tase (Boehringer Mannheim Biochemicals, Mannheim,
Germany). After a 45-minute incubation, proteins were
precipitated with 70% zinc sulfate solution and samples
were centrifuged at 14,000g for five minutes. One hun-
dred L of sample was then mixed with 100 L Griess
reagent (0.05% N-(1-naphthyl) ethylene diamine dihy-
drochloride, 0.5% sulfanilamide in 45% glacial acetic acid)
in 96-well plates. After a 10-minute incubation in the dark,
absorbance was read at 570 nm in an automated plate
reader (MRX II, Dynex Technologies, Frankfurt am Main,
Germany). Standard samples were prepared with sodium
nitrate and were also nitrate reductase–treated.
Effect of NO on glomerular TGF-1 production in vitro
To demonstrate that NO directly regulates TGF-
production in vitro, glomeruli from 2 normal and 3 ne-
phritic (day 7 after injection of 0.5 mg/kg body weight
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Fig. 1. L-Arginine intake in rats with anti-thy1 glomerulonephritis (GN)
treated with supplemental L-arginine (GN-Arg), supplemental L-argi-
nine and L-NAME (GN-Arg-NAME), or molsidomine (GN-Molsi).
Normal control animals (control) received an injection with phosphate-
buffered saline (PBS). *** P  0.001 vs. GN
OX-7) rats were resuspended in DMEM culture medium
at a density of 2000/mL. The NO donor diethylenetria-
mine (DETA) (NONOate) was added in increasing con-
centrations: 0 (control), 10, 50, 100, and 500 mol/L. The
doses were chosen on the basis of a previous report [21].
After 48 hours incubation at 37C/5% CO2, supernatants
were harvested and stored at 20C until analysis of
glomerular TGF-1 production. Three samples from
each animal and DETA NONOate concentration were
analyzed.
Statistical analysis
Data are expressed as mean  standard error of the
mean (SEM). Statistical analysis between the groups was
performed by analysis of variance (ANOVA) and subse-
quent t testing with Bonferroni correction for multiple
comparisons. Data on mRNA expression were analyzed
by Mann-Whitney-U test. A P value 0.05 was consid-
ered significant.
RESULTS
Protocol 1: Effects 7 days after induction of anti-thy1
glomerulonephritis
Body weight, l-arginine, L-NAME, and molsidomine
intake. The body weights at the end of the experiment
were not significantly different between the groups. The
l-arginine intake actually achieved is depicted in Figure 1.
Compared to the normal control (218  0.0 mg/day) and
the untreated nephritic animals (212  4 mg/day), l-argi-
nine supplementation significantly increased l-arginine
Fig. 2. Effects of supplemental L-arginine (GN-Arg), supplemental
L-arginine and low-dose nitro-L-arginine-methyl ester (L-NAME) (GN-
Arg-NAME), or molsidomine (GN-Molsi) on systolic blood pressure
7 days after induction of acute anti-thy1 glomerulonephritis (GN). Di-
etary modifications were started 24 hours after injection of anti-thy1
antibody. Normal control animals (control) received a phosphate-buf-
fered saline (PBS) injection.
intake in the GN-Arg (677  19 mg/day, P  0.001) and
GN-Arg-NAME group (625  43 mg/day, P  0.001).
In the GN-Molsi group (218  0.0 mg/day), l-arginine
intake was similar to the normal control and untreated
GN animals. In the GN-Arg-NAME group, an actual
L-NAME intake of 2.6 0.3 mg/day/animal was achieved;
in the GN-Molsi group a molsidomine intake of 10.0 
0.2 mg/day/animal was achieved.
Blood pressure and proteinuria. As shown in Figure 2,
systolic blood pressure was normal in the normal control
and the untreated GN group (123  5 mm Hg and 125 
3 mm Hg, respectively). Administration of l-arginine
(118  6 mm Hg), l-arginine and L-NAME (124  6
mm Hg), or molsidomine (116  6 mm Hg) slightly, but
not significantly, affected systolic blood pressure (P 
NS for all groups). In comparison to the normal controls
(13  2 mg/day), proteinuria was significantly elevated
in the untreated anti-thy1 animals (48  5 mg/day). In
the treatment groups, proteinuria was not significantly
altered by addition of l-arginine (62  7 mg/day), l-argi-
nine and L-NAME (64  6 mg/day), or molsidomine
(48  6 mg/day) (P  NS vs. GN for all groups).
Markers of endogenous NO production. Nitrite	nitrate
(NOx) was measured in two types of samples, plasma
and 24-hour urine. The results are depicted in Figure 3.
Induction of anti-thy1 glomerulonephritis did not sig-
nificantly affect day 7 plasma NOx levels (control, 33 
4 nmol/mL vs. GN, 36  2 nmol/mL, P  NS) or urinary
NOx excretion (control, 14.0  0.54 mol/24 hour vs.
GN, 13.9 1.58 mol/24 hour, PNS). Administration
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Fig. 3. Effects of supplemental L-arginine (GN-Arg), supplemental
L-arginine and low-dose L-NAME (GN-Arg-NAME), or molsidomine
(GN-Molsi) on plasma NOx (A) and urinary NOx excretion (B) 7 days
after induction of acute anti-thy1 GN. Dietary modifications were started
24 hours after injection of anti-thy1 antibody. Normal control animals
(control) received a phosphate-buffered saline (PBS) injection. *P 
0.05 vs. GN; **P  0.01 vs. GN.
of l-arginine alone or together with L-NAME did not
significantly alter plasma (GN-Arg, 39  4 nmol/mL,
GN-Arg-NAME, 36  3 nmol/mL, P  NS vs. control
and GN) and urine NOx concentrations (GN-Arg, 18.11
2.73mol/24 hours, GN-Arg-NAME, 15.80 2.28mol/
24 hours, P  NS vs. control and GN). In contrast, treat-
ment with molsidomine significantly increased NOx lev-
els in plasma and urine (56  8 mol/mL, P  0.05 vs.
control and GN, and 29.27  3.73 mol/24 hours, P 
0.01 vs. control and GN, respectively).
Markers of fibrotic response
Glomerular matrix expansion and protein expression
of TGF-b1, fibronectin, and PAI-1. As shown in Figure 4,
glomerular TGF-1 protein expression (Fig. 4A) closely
followed the changes seen in histologic matrix deposition
(Fig. 4B). Compared to the untreated anti-thy1 animals,
both l-arginine and molsidomine administration reduced
glomerular TGF-1 protein expression (GN, 1023  71
pg/mL vs. GN-Arg, 522 66 pg/mL and GN-Molsi, 629
34 pg/mL, P 0.001) and the histologic matrix score (GN,
76.0  1.7% vs. GN-Arg, 67.1  3.9%, P 0.05 and GN-
Molsi, 62.7  2.0%, P  0.01). Concomitant L-NAME
treatment almost completely reversed the beneficial l-argi-
nine effect (TGF-1, 967 46 pg/mL, matrix score 74.0
2.5%, respectively, P 0.01 vs. GN-Arg, PNS vs. GN).
Figure 5 illustrates characteristic immunohistochemic
staining for TGF-1 protein in the experimental groups.
To arrive at an indication of the TGF- activity in
vivo, the expressions of the matrix protein fibronectin
and the protease inhibitor PAI-1 were analyzed (Fig.
6). Glomerular protein production of fibronectin in the
untreated nephritic animals reached 23.3  1.2 g/mL
(Fig. 6A), production of PAI-1 increased up to 1060 
93 ng/mL (Fig. 6B), respectively. Similar to the expres-
Fig. 4. Effects of supplemental L-arginine (GN-Arg), supplemental
L-arginine and low-dose nitro-L-arginine-methyl ester (L-NAME) (GN-
Arg-NAME), or molsidomine (GN-Molsi) on the glomerular protein
expression of the key fibrosis mediator transforming growth factor
(TGF)-1 (A) and glomerular matrix accumulation (B) 7 days after
induction of acute anti-thy1 GN. Dietary modifications were started 24
hours after injection of anti-thy1 antibody. For determining TGF-
protein expression, glomeruli were harvested from individual animals
and cultured at a density of 2000 per mL for 48 hours. *P  0.05; **P 
0.01; ***P  0.001 vs. GN.
sion of TGF-1, both l-arginine and molsidomine re-
duced fibronectin (GN-Arg, 16.4  1.2 g/mL, GN-
Molsi, 15.8  1.0 g/mL, P  0.001 vs. GN) and PAI-1
protein expression (GN-Arg, 757  43 ng/mL, GN-
Molsi, 723 64 ng/mL, P 0.05 vs. GN). Again, concom-
itant L-NAME treatment reversed the beneficial l-argi-
nine effect (fibronectin, 23.4  1.2 g/mL, PAI-1, 953 
69 ng/mL, respectively, P  0.05 vs. GN-Arg, P  NS
vs. GN).
Glomerular mRNA expression of TGF-b1, fibronectin,
and PAI-1. The relative glomerular expression of TGF-1,
fibronectin, and PAI-1 mRNA corrected for GAPDH is
depicted in Figure 7. The mRNA expression pattern of
the matrix components followed the protein expression.
Compared to the untreated anti-thy1 animals (100%),
both l-arginine and molsidomine reduced glomerular
mRNA expression of TGF-1 (GN-Arg, 68  8%, GN-
Molsi, 63  8%, P  0.001), fibronectin (GN-Arg, 62 
5%, GN-Molsi, 63  6%, P  0.001), and PAI-1 (GN-
Arg, 81  7%, GN-Molsi, 75  4%, P  0.001). The
beneficial effect of l-arginine supplementation was abol-
ished by parallel L-NAME treatment (TGF-1, 105 
14%, fibronectin, 90  10%, and PAI-1, 109  17%,
respectively, P  NS vs. GN).
Protocol 2: Effects 12 days after induction of
anti-thy1 glomerulonephritis
Basic data. l-arginine, L-NAME, and molsidomine
intake was comparable to protocol 1. Body weights were
not significantly different between the experimental groups
12 days after disease induction. The results on blood
pressure, proteinuria, and markers of endogenous NO
production were similar to protocol 1 (data not shown).
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Fig. 5. Characteristic staining for renal trans-
forming growth factor (TGF)-1 protein in nor-
mal control (A), anti-thy1 nephritic rats with
no treatment [glomerulonephritis (GN)] (B),
supplemental L-arginine (GN-Arg) (C), supple-
mental L-arginine and low-dose nitro-L-arginine-
methyl ester (L-NAME) (GN-Arg-NAME)
(D ), or molsidomine (GN-Molsi) (E ) 7 days
after disease induction.
Fig. 6. Effects of supplemental L-arginine (GN-Arg), supplemental
L-arginine and nitro-L-arginine-methyl ester (L-NAME) (GN-Arg-
NAME), or molsidomine (GN-Molsi) on the protein expression of the
matrix protein fibronectin (A ) and the protease inhibitor plasminogen
activator inhibitor type 1 (PAI-1) (B ) 7 days after induction of acute
anti-thy1 glomerulonephritis (GN). Glomeruli were harvested from
individual animals and cultured at a density of 2000 per mL for 48
hours. *P  0.05; ***P  0.001 vs. GN.
Glomerular matrix expansion and protein expression
of TGF-b1, fibronectin, and PAI-1. Compared to the
normal control, untreated nephritic animals showed sig-
nificantly increased glomerular matrix accumulation (con-
trol, 30.0  5.0% vs. GN, 65.4  2.6%, P  0.01) and
protein expression of TGF-1 (control, 60  11 pg/mL
vs. GN, 282 15 pg/mL, P 0.001), fibronectin (control,
2.7  0.5 g/mL vs. GN, 17.6  1.5 g/mL, P  0.001),
and PAI-1 (control, 143  17 ng/mL vs. GN, 758  78
ng/mL, P  0.001) (Fig. 8 A to D). As an observation
of interest, the absolute levels at day 12 were lower than
in the day 7 nephritic animals, indicating beginning resolu-
tion of anti-thy1 glomerulonephritis. Similar to protocol
1, both l-arginine and molsidomine reduced histologic
matrix accumulation (GN-Arg, 55.8  1.8%, P  0.01,
and GN-Molsi, 53.9  3.5%, P  0.05 vs. GN, respec-
tively), as well as expression of TGF-1 (GN-Arg, 167
13 pg/mL and GN-Molsi, 158  11 pg/mL, both P 
0.001 vs. GN), fibronectin (GN-Arg, 11.9  0.9 g/mL
and GN-Molsi, 11.8 1.2 g/mL, both P 0.01 vs. GN),
and PAI-1 (GN-Arg, 624  80 ng/mL and GN-Molsi,
521  69 ng/mL, P  0.05 vs. GN). Consistent with the
protocol 1 data, concomitant administration of L-NAME
reversed the antifibrotic action of l-arginine (matrix
score, 62.6 1.0%, TGF-1, 275 26 pg/mL, fibronectin,
15.3  0.8 g/mL, and PAI-1, 968  130 ng/mL, all P 
0.05 vs. GN-Arg).
Effect of NO on glomerular TGF-b1 production in
vitro. As shown in Figure 9, the effect of the NO donor
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Fig. 7. Effects of supplemental L-arginine (GN-Arg), supplemental
L-arginine and low-dose (L-NAME) (GN-Arg-NAME), or molsidomine
(GN-Molsi) on glomerular mRNA expression of transforming growth
factor (TGF)-1 (A ), fibronectin (B ), and plasminogen activator inhibi-
tor type 1 (PAI-1) (C ) relative to the housekeeping gene glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) 7 days after induction of
acute anti-thy1 glomerulonephritis (GN). The mRNA expression is
depicted in relation to the untreated nephritic group. A representative
polymerase chain reaction (PCR) product gel is shown (D ). ***P 
0.01 vs. GN.
DETA NONOate was analyzed in cultured glomeruli
harvested from normal and day 7 anti-thy1 nephritic
animals. In both, increasing concentrations of NO sig-
nificantly decreased glomerular 48-hour TGF-1 protein
production in a dose-dependent manner. In normal glo-
meruli, 10, 50, 100, and 500 mol DETA NONOate
reduced TGF-1 synthesis by 18%, 43%, 63%, and 68%,
and in nephritic glomeruli by 1%, 12%, 18%, and 38%,
respectively.
DISCUSSION
A deficiency in NO synthesis, probably derived from
eNOS, characterizes numerous kidney diseases [4–7, 22].
In human kidney disease, a low NO state has been found
in hypertension, immunoglobulin A (IgA) nephropathy,
and chronic renal insufficiency [22]. In experimental mod-
els, diminished NO synthesis has been documented in
rats with subtotal nephrectomy, hypertensive-, obstruc-
tive-, and cholesterol feeding–induced nephropathy [7, 15].
Fig. 8. Effects on glomerular matrix accumulation (A ) and the protein
expression of transforming growth factor-beta1 (TGF)-1 (B ), fibro-
nectin (C ), and plasminogen activator inhibitor type 1 (PAI-1) (D ) 12
days after induction of acute anti-thy1 glomerulonephritis (GN). The
animals were treated with supplemental l-arginine (GN-Arg), supple-
mental l-arginine and low-dose (L-NAME) (GN-Arg-NAME), or mol-
sidomine (GN-Molsi). Treatments were started 24 hours after injection
of anti-thy1 antibody. Glomeruli were harvested from individual ani-
mals and cultured at a density of 2000 per mL for 48 hours. *P  0.05;
**P  0.01; ***P  0.001 vs. GN.
Reduced NO production has been linked to insufficient
supply of its precursor, l-arginine [4–7]. In rodents and
humans, intake of this amino acid is “semi-essential” [23].
This term expresses that, under normal physiologic con-
ditions, endogenous l-arginine generation is sufficient for
maintaining whole body l-arginine homeostasis. How-
ever, when l-arginine turnover increases, as in growth,
inflammation, or tissue repair, dietary supply can become
rate-limiting for the l-arginine metabolizing pathways
[7, 23]. Indeed, low l-arginine levels have been docu-
mented in experimental kidney disease, including the anti-
thy1 glomerulonephritis model used in this study [10, 24].
The results of the present study confirm and expand
those of a previous one on anti-thy1 glomerulonephritis,
which showed that high l-arginine intake limits glomeru-
lar matrix protein production and accumulation during
the repair phase of this model [10]. Beyond this, our results
show that the beneficial effect of l-arginine is abolished
when a low dose of the NOS inhibitor L-NAME is adminis-
tered, and that the NO donor molsidomine is antifibrotic
in a manner similar to l-arginine. Thus, the present study
shows that endogenous production of NO is the main
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Fig. 9. Effects of the nitric oxide (NO) donor diethylenetriamine
(DETA) NONOate on glomerular normal (A ) and nephritic (B ) trans-
forming growth factor (TGF)-1 production in vitro. Glomeruli were
harvested from individual animals and cultured at a density of 2000 per
mL for 48 hours in the presence of the indicated concentrations of
DETA NONOate. *P  0.05; **P  0.01; ***P  0.001 vs. GN.
molecular mechanism that underlies the antifibrotic ef-
fect of l-arginine supplementation in this model, and
that other l-arginine metabolizing pathways may play
only a minor role. In another recent study [9] that is of
interest to the present one, administration of the l-argi-
nine metabolite agmatine has been shown to reduce pro-
liferation and matrix expansion in a similar model of
anti-thy1 glomerulonephritis. Although the other study
documents that agmatine is beneficial, it does not show
that this pathway is involved in mediating the antifibrotic
actions of l-arginine supplementation.
Blood levels or urinary excretion of nitrate/nitrite have
frequently been used as indices of endogenous NO pro-
duction [25]. The association between l-arginine admin-
istration, NO generation, and the benefits found in previ-
ous renal studies has led to the general assumption that
activation of the l-arginine/eNOS pathway is the respon-
sible mechanism [26, 27]. However, the results presented
were mainly descriptive and did not prove that NO is
the mediator. Other metabolites may still be involved.
In addition, plasma and urinary NOx levels represent
whole body NO generation and may not be, in all cases,
sensitive enough to detect changes in renal NO produc-
tion [25]. Consistent with this, l-arginine supplementa-
tion slightly, but not significantly, altered plasma and
urinary NOx levels in the present study during the repair
phase of anti-thy1 glomerulonephritis. Other studies em-
ployed inhibition of NO synthesis in parallel to l-arginine
supplementation to provide evidence for the involvement
of the l-arginine/NO pathway [26, 28]. Although this
approach is more informative than measuring NOx lev-
els, systemic inhibition of NO synthesis itself leads to
renal fibrosis [29]. In addition, in the presence of pre-
existing renal tissue damage, NO inhibition may proba-
bly synergistically amplify renal matrix production. Re-
versal of a benefit of l-arginine supplementation in this
context may therefore not prove NO dependence. To
overcome these potential methodologic limitations, we
used a dual pharmacologic approach combining both
NO synthesis inhibition and NO donation.
Renal tissue injury by hypertension is both an impor-
tant cause and progression factor of chronic kidney dis-
ease. Since the positive effects of l-arginine supplemen-
tation went in parallel with lower blood pressure levels
[4, 26], it has been generally thought that l-arginine en-
hances deficient endothelial NO production, and thereby
prevents hypertensive renal tissue injury and subsequent
matrix expansion. Beyond this, the present data imply
that an additional direct, pressure-independent action of
relatively low levels of NO, probably derived from eNOS,
on the molecular cascade of tissue repair (i.e., expression
of TGF-) may play an important role. In the model of
acute anti-thy1 glomerulonephritis, matrix expansion is
a response to an immunologic insult and hemodynamic
injury is no major element [7]. Blood pressure remains
normal in anti-thy1 glomerulonephritis, and even super-
imposing hypertension does not affect matrix accumula-
tion [30]. It is also of importance that our maneuvers to
alter endogenous l-arginine/NO metabolism in anti-thy1
glomerulonephritis did not change blood pressure sig-
nificantly. This study therefore suggests that NO inter-
acts with the in vivo overexpression of TGF- and matrix
expansion through a direct, pressure-independent mech-
anism.
Supporting this notion, the NO donor DETA NONOate
directly reduced TGF-1 production of cultured normal
and anti-thy1 nephritic glomeruli in vivo. This finding is
consistent with previous studies in cultured rat mesangial
cells, in which administration of NO donors, induction
of endogenous NO production, or coculture with glomer-
ular endothelial cells suppressed TGF-1 and subsequent
collagen synthesis [31]. Other in vitro studies have docu-
mented that addition of NO reduces matrix protein syn-
thesis in rat mesangial cells and vascular smooth muscle
cells, although the molecular mechanism (i.e., expression
of TGF-1) was not further analyzed [28]. Expanding
the importance of these in vitro findings, the present
study suggests that this direct paracrine mechanism is
also operative in fibrotic renal disease in vivo and may
be relevant for the antifibrotic effects of l-arginine ob-
served in hypertensive renal fibrosis.
In contrast to glomerular TGF- expression and other
measures of fibrotic disease, proteinuria was not further
altered by our approaches to modify renal NO synthesis.
With regard to l-arginine supplementation, this finding
is consistent with the previous experiment in anti-thy1
glomerulonephritis [10]. The reasons for this are unclear,
but may be related to the anti-thy1 glomerulonephritis
model, in which some rat strains do not develop protein-
uria, while in others, the degree of proteinuria varies
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far more than the fibrotic response, depending on the
antibody or antiserum used to produce disease [10].
Compared to supplementation of l-arginine, pharma-
cologic NO donation as performed in this study allows
a more clearly defined increase in endogenous NO syn-
thesis. We chose molsidomine because this drug is less
prone to loss of action due to tolerance than the also
clinically widely used nitric acid esters [16]. This advan-
tage has been linked to the fact that the active metabolite
SIN-1 releases NO spontaneously, while the organic ni-
trates require enzymatic bioactivation. Judged on the
basis of plasma and urinary NOx levels, molsidomine
appears to be a much more effective mode of NO dona-
tion. However, this may not be true at the renal and
glomerular level. NO release of SIN-1 is distributed un-
specifically over the whole body [16]. In contrast, l-argi-
nine supplementation may facilitate a more spatially pre-
cise NO donation, because it releases NO at exactly that
place where it is naturally generated and the NO signal
transduction cascade required to mediate the NO actions
is already lined up.
The results in acute normotensive renal matrix accu-
mulation are consistent with recent data in a chronic
model of hypertensive remnant kidney [13]. Here, molsi-
domine normalized blood pressure, partly reduced pro-
teinuria, and prolonged survival. In a side-by-side com-
parison, molsidomine was less effective than a high dose
of the angiotensin-converting enzyme (ACE) inhibitor
lisinopril. Further benefits of molsidomine were recently
described in models of ischemia/reperfusion and choles-
terol-fed hypertensive renal fibrosis [15, 32]. However,
negative outcomes using molsidomine have recently been
found in one study on proteinuric adriamycin nephropa-
thy [14]. This negative action has been linked to the
potential for prooxidant activity, which NO donors may
have under certain circumstances.
In immune-mediated kidney disease with predominant
expression of iNOS, l-arginine supplementation has shown
negative effects [7, 33]. NO produced in high concentra-
tions by iNOS amplifies renal tissue injury, which then
serves as a strong stimulus for TGF- overexpression.
Inducible NO synthesis has been identified as a key inju-
rious stimulus in experimental anti-thy1–induced mesan-
gial cell lysis, acute tubular necrosis, renal transplant
rejection, and murine lupus nephritis [12, 34–36]. In hu-
man renal disorders, increased expression of iNOS mRNA
and protein has been documented in mesangioprolifera-
tive glomerulonephritis, Wegener’s granulomatosis, lu-
pus nephritis, and kidney transplant rejection [7, 37], and
correlated with histologic signs of renal damage and loss
of renal function [37]. Dietary l-arginine supplementa-
tion performed in a similar way as in this study resulted
in more severe immune-mediated tissue injury and sub-
sequent matrix deposition during the acute mesangial
cell lysis phase of anti-thy1 glomerulonephritis, as well
as in chronic progressive MRL/lpr lupus nephritis
[33, 38]. The present study suggests that exclusive NO
donation may be a reasonable strategy to overcome this
important limitation of l-arginine supplementation in
treating fibrotic renal disease.
Moreover, two recent trials of supplementing l-argi-
nine in patients with renal disease were also disappoint-
ing [39] (abstract; Eisenberger, J Am Soc Nephrol 10:
727–728A, 1999). Of interest is the fact that both were
performed in diseases with known expression of iNOS,
one in chronic glomerulonephritis, the other in kidney
transplant recipients. Although the reasons are unclear,
the negative outcome may reflect that beneficial l-argi-
nine effects were neutralized by simultaneous detrimen-
tal effects of increased iNOS-mediated NO production.
The benefits of NO donors such as molsidomine have
not been tested in renal clinical trials yet. However, the
results of the present study and of those mentioned
above imply that exclusive pharmacologic NO donation
may be a novel and more specific approach to treat
human fibrotic renal disease.
CONCLUSION
The present study shows that NO mediates the bene-
ficial effect of l-arginine supplementation on TGF-
overexpression and matrix accumulation following the
induction of anti-thy1 glomerulonephritis and suggests
that NO reduces TGF- overexpression in vivo through
a blood pressure–independent, paracrine mechanism.
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